Armistice Capital’s Voyager Therapeutics VYGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12M | Sell |
3,436,000
-64,000
| -2% | -$243K | 0.15% | 95 |
|
|
2026
Q1 | $13.5M | Sell |
3,500,000
-500,000
| -13% | -$1.97M | 0.24% | 75 |
|
|
2025
Q4 | $15.7M | Sell |
4,000,000
-200,000
| -5% | -$885K | 0.19% | 81 |
|
|
2025
Q3 | $19.6M | Sell |
4,200,000
-600,000
| -13% | -$2.17M | 0.29% | 52 |
|
|
2025
Q2 | $14.9M | Sell |
4,800,000
-636,000
| -12% | -$2.05M | 0.26% | 53 |
|
|
2025
Q1 | $18.4M | Buy |
5,436,000
+40,000
| +0.7% | +$187K | 0.28% | 69 |
|
|
2024
Q4 | $30.6M | Buy |
5,396,000
+196,000
| +4% | +$1.26M | 0.42% | 46 |
|
|
2024
Q3 | $30.4M | Hold |
5,200,000
| – | – | 0.49% | 37 |
|
|
2024
Q2 | $41.1M | Buy |
5,200,000
+528,000
| +11% | +$4.43M | 0.52% | 33 |
|
|
2024
Q1 | $43.5M | Buy |
4,672,000
+436,000
| +10% | +$3.68M | 0.58% | 29 |
|
|
2023
Q4 | $35.8M | Buy |
4,236,000
+58,000
| +1% | +$421K | 0.49% | 36 |
|
|
2023
Q3 | $32.4M | Buy |
4,178,000
+554,000
| +15% | +$5.06M | 0.5% | 39 |
|
|
2023
Q2 | $41.5M | Buy |
3,624,000
+100,000
| +3% | +$1.03M | 0.6% | 39 |
|
|
2023
Q1 | $27.2M | Buy |
3,524,000
+128,000
| +4% | +$1.02M | 0.39% | 51 |
|
|
2022
Q4 | $20.7M | Hold |
3,396,000
| – | – | 0.36% | 51 |
|
|
2022
Q3 | $20.1M | Buy |
3,396,000
+832,000
| +32% | +$5.33M | 0.35% | 59 |
|
|
2022
Q2 | $15.2M | Buy |
2,564,000
+564,000
| +28% | +$3.81M | 0.26% | 68 |
|
|
2022
Q1 | $15.2M | Buy |
+2,000,000
| New | +$8.92M | 0.29% | 65 |
|
|
2021
Q4 | – | Sell |
-3,716,000
| Closed | -$9.77M | – | 178 |
|
|
2021
Q3 | $9.77M | Hold |
3,716,000
| – | – | 0.17% | 91 |
|
|
2021
Q2 | $15.3M | Hold |
3,716,000
| – | – | 0.27% | 75 |
|
|
2021
Q1 | $17.5M | Buy |
3,716,000
+324,000
| +10% | +$2.21M | 0.4% | 63 |
|
|
2020
Q4 | $24.3M | Buy |
3,392,000
+692,000
| +26% | +$6.65M | 0.82% | 37 |
|
|
2020
Q3 | $28.8M | Buy |
2,700,000
+622,000
| +30% | +$7.3M | 1.05% | 36 |
|
|
2020
Q2 | $26.2M | Sell |
2,078,000
-158,000
| -7% | -$1.84M | 1.15% | 36 |
|
|
2020
Q1 | $20.5M | Buy |
2,236,000
+612,000
| +38% | +$7.02M | 1.27% | 34 |
|
|
2019
Q4 | $22.7M | Buy |
1,624,000
+528,000
| +48% | +$7.67M | 1.31% | 26 |
|
|
2019
Q3 | $18.9M | Buy |
1,096,000
+160,000
| +17% | +$3.36M | 1.25% | 31 |
|
|
2019
Q2 | $25.5M | Sell |
936,000
-600,000
| -39% | -$13.7M | 1.61% | 22 |
|
|
2019
Q1 | $29.4M | Sell |
1,536,000
-1,300,000
| -46% | -$16.9M | 1.61% | 21 |
|
|
2018
Q4 | $26.7M | Buy |
2,836,000
+1,112,000
| +65% | +$14.3M | 2.02% | 14 |
|
|
2018
Q3 | $32.6M | Buy |
1,724,000
+1,292,000
| +299% | +$24.8M | 1.96% | 18 |
|
|
2018
Q2 | $8.44M | Buy |
+432,000
| New | +$8.54M | 0.55% | 50 |
|
Other funds holding VYGR
VPC
OM
Armistice Capital's VYGR Position: Q2 2026 in Review
Armistice Capital reduced its Voyager Therapeutics (VYGR) stake by 1.8% in Q2 2026, selling an estimated $243K and leaving 3,436,000 shares worth $12M. The position accounts for 0.15% of the portfolio, ranked #95.
Armistice Capital first reported a position in VYGR in Q2 2018 and has held it in 32 quarters since. The position peaked at $43.5M in Q1 2024. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.
- Armistice Capital held 3,436,000 shares of Voyager Therapeutics worth $12M as of Q2 2026.
- Armistice Capital sold 64,000 Voyager Therapeutics shares in Q2 2026, an estimated $243K.
- Voyager Therapeutics made up 0.15% of Armistice Capital's portfolio in Q2 2026, its #95 holding.
- Armistice Capital first reported a position in Voyager Therapeutics in Q2 2018 and has held it in 32 quarters since.
- Armistice Capital's Voyager Therapeutics position peaked at $43.5M in Q1 2024.
- 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.
Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.